MedTrace Logo

A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

NCT01357148 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2015-08-10

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Sitagliptin Phosphate/Metformin HCl (JANUMET®)

Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-05-31
Completion
2010-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357148 on ClinicalTrials.gov